Ghisallo Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Ghisallo Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-125,000	Closed	-$5.1M	–	151
2023 Q2	$5.1M	Hold	125,000	–	–	0.61%	42
2023 Q1	$4.66M	Sell	125,000 -125,000	-50%	-$4.9M	1.12%	22
2022 Q4	$8.72M	Buy	+250,000	New	+$11.9M	1.55%	15
2021 Q4	–	Sell	-20,000	Closed	-$2.68M	–	501
2021 Q3	$2.68M	Sell	20,000 -15,000	-43%	-$2.27M	0.1%	241
2021 Q2	$5.67M	Buy	+35,000	New	+$2.73M	0.22%	118

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ghisallo Capital Management's NTLA Position: Q3 2023 in Review

Ghisallo Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 125,000 shares — an estimated $5.1M sold.

Ghisallo Capital Management first reported a position in NTLA in Q2 2021 and held it in 5 quarters. The position peaked at $8.72M in Q4 2022. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

Ghisallo Capital Management reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
Ghisallo Capital Management sold 125,000 Intellia Therapeutics shares in Q3 2023, an estimated $5.1M.
Ghisallo Capital Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 5 quarters.
Ghisallo Capital Management's Intellia Therapeutics position peaked at $8.72M in Q4 2022.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Ghisallo Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.